• Home
  • 2nd OP
  • CMP™ CLASS
  • COACH
  • EDITOR
  • ELECT DR KENT
  • SPONSOR
  • e-BOOKS
  • “MEDICAL EXECUTIVE-POST”
  • Why Post Your e-Content or Print Publish with Us?
  • Job Posts Classified Ads
  • Why Subscribe to the ME-P?

The Leading Business Education Network for Doctors, Financial Advisors and Health Industry Consultants

Entries RSS | Comments RSS
  • Member Statistics

    • 944,278 Colleagues-to-Date [Sponsored by a generous R&D grant from iMBA, Inc.]
  • ME-P Information & Content Channels

  • Ann Miller RN MHA [Managing Editor]

    ME-P SYNDICATIONS:
    WSJ.com,
    CNN.com,
    Forbes.com,
    WashingtonPost.com,
    BusinessWeek.com,
    USNews.com, Reuters.com,
    TimeWarnerCable.com,
    e-How.com,
    News Alloy.com,
    and Congress.org

    Comprehensive Financial Planning Strategies for Doctors and Advisors: Best Practices from Leading Consultants and Certified Medical Planners(TM)

    Product Details

    Product Details

    Product Details

  • CERTIFIED MEDICAL PLANNER® program

    New "Self-Directed" Study Option SinceJanuary 1, 2020
  • Most Recent ME-Ps

    • DAILY UPDATE: US Budget Deal Passes House to Avoid Debt Ceiling -while- Closing Markets End May on Weak Note
    • PODCAST: Hospital Out Patient Pricing Explained
    • PHYSICIANS: Mentoring & Second Opinions
    • DAILY UPDATE: Worker Health Insurance Value and Major Market Benchmarks
    • Become a Board CERTIFIED MEDICAL PLANNER™ and Thrive
    • ENVISION HEALTHCARE : KKR Backed and Bankrupt!
    • DAILY UPDATE: Elizabeth Holmes to Jail 2 Day & A.I.
    • PODCASTS: Avoid 5 Marketing Mistakes Financial Advisors Make Engaging Doctors & More!
    • CHARTER COMMUNICATIONS: Why We’re Confident in Our Investment
    • FIDUCIARY: Obtain an Unbiased 2nd Financial Advisory Opinion
    • STUDY: ChatGPT Out Performs Doctors?
    • DEATH: Eco-Friendly Transitions and Interment
    • HAPPY: 529 Day
    • WALL $TREET: Memorial Day 2023
    • DR KENT: I’m Saluting a Real American Hero on Memorial Day!
    • DAILY UPDATE: U.S. Debt Ceiling Tentative Deal? … and Nvidia
    • RE-PODCAST: Financial Implications of Ozempic, Wegovy and Mounjaro
    • Honoring Memorial Day 2023
    • DAILY UPDATE: Doug Kass Speaks on the Markets
    • PODCAST: Venture Capital in Healthcare VS. Boot Strapping
    • What is Cyber-Security SPOOFING and PHISHING?
    • DAILY UPDATE: Nvidia Chips Launch NASDAQ as Fitch Questions US Credit Rating
    • DR KENT: May is Mental Health Month
    • Pediatric Mental Health Month is Also in May
    • What is a Social Impact Bond?
  • PodiatryPrep.org


    BOARD CERTIFICATION EXAM STUDY GUIDES
    Lower Extremity Trauma
    [Click on Image to Enlarge]

  • ME-P Free Advertising Consultation

    The “Medical Executive-Post” is about connecting doctors, health care executives and modern consulting advisors. It’s about free-enterprise, business, practice, policy, personal financial planning and wealth building capitalism. We have an attitude that’s independent, outspoken, intelligent and so Next-Gen; often edgy, usually controversial. And, our consultants “got fly”, just like U. Read it! Write it! Post it! “Medical Executive-Post”. Call or email us for your FREE advertising and sales consultation TODAY [770.448.0769]

    Product Details

    Product Details

    Product Details
  • Medical & Surgical e-Consent Forms

    ePodiatryConsentForms.com
  • iMBA Inc., OFFICES

    Suite #5901 Wilbanks Drive, Norcross, Georgia, 30092 USA [1.770.448.0769]. Our location is real and we are now virtually enabled to assist new long distance clients and out-of-town colleagues.

  • ME-P Publishing

  • SEEKING INDUSTRY INFO PARTNERS?

    If you want the opportunity to work with leading health care industry insiders, innovators and watchers, the “ME-P” may be right for you? We are unbiased and operate at the nexus of theoretical and applied R&D. Collaborate with us and you’ll put your brand in front of a smart & tightly focused demographic; one at the forefront of our emerging healthcare free marketplace of informed and professional “movers and shakers.” Our Ad Rate Card is available upon request [770-448-0769].

  • Reader Comments, Quips, Opinions, News & Updates

    • Anonymous on The Benefits of Dentistry Unhurried
    • DEATH: Eco-Friendly Transitions and Interment | The Leading Business Education Network for Doctors, Financial Advisors and Health Industry Consultants on How Health Technology Entrepreneurs and Innovators are Streamlining Death!
    • Dr. Marcinko on Honoring Memorial Day 2023
    • The History of Memorial Day | The Leading Business Education Network for Doctors, Financial Advisors and Health Industry Consultants on The Bonze Star Medal Confirmed
    • About Crowd-Med [Case Review Service] | The Leading Business Education Network for Doctors, Financial Advisors and Health Industry Consultants on Is Medical Licensing Really Necessary?
    • About Crowd-Med [Case Review Service] | The Leading Business Education Network for Doctors, Financial Advisors and Health Industry Consultants on Will Future Doctors Need a Medical License?
    • Anonymous on RIGHTS: Mental Health in America [Georgia]
    • Klinesmith RN on SOCIAL MEDIA: Dr. Vivek Murthy Warns on Children’s Mental Health
    • Dr Kent Mercado JD on SOCIAL MEDIA: Dr. Vivek Murthy Warns on Children’s Mental Health
    • Dr. Marcinko on Supreme Court Hears Oral Arguments on 340B Drug Pricing Cuts
    • RIGHTS: Mental Health in America [Georgia] | The Leading Business Education Network for Doctors, Financial Advisors and Health Industry Consultants on A Review of Mental Healthcare Provider Types
    • Anonymous on 2018 – 2021 HSA Contribution Limits
    • Dr. Marcinko on On Childhood Obesity Trends
    • Doctor – Are You on Your Way to $5.5 Million? | The Leading Business Education Network for Doctors, Financial Advisors and Health Industry Consultants on Taxing the [not so] Rich [doctors]
    • Doctor – Are You on Your Way to $5.5 Million? | The Leading Business Education Network for Doctors, Financial Advisors and Health Industry Consultants on Are Doctors NOW Members of the Middle Class?
  • Start-Up Advice for Businesses, DRs and Entrepreneurs

    ImageProxy “Providing Management, Financial and Business Solutions for Modernity”
  • Up-Trending ME-Ps

    • "MEDICAL EXECUTIVE-POST"
    • ELECT DR KENT
    • DR KENT: May is Mental Health Month
    • ASPEN DENTAL: Cyber Attack with Data Breach
    • Accuracy versus Precision?
    • PRESS RELEASE: DR. Kent Mercado JD for Congress
    • The Top 15 "Evolutions of Learning"
    • ENVISION HEALTHCARE : KKR Backed and Bankrupt!
    • Medication Non-Adherence Rates
    • VIDEO: What is the "Baltimore Nod"?
  • Capitalism and Free Enterprise Advocacy

    Whether you’re a mature CXO, physician or start-up entrepreneur in need of management, financial, HR or business planning information on free markets and competition, the "Medical Executive-Post” is the online place to meet for Capitalism 2.0 collaboration. Support our online development, and advance our onground research initiatives in free market economics, as we seek to showcase the brightest Next-Gen minds. THE ME-P DISCLAIMER: Posts, comments and opinions do not necessarily represent iMBA, Inc., but become our property after submission. Copyright © 2006 to-date. iMBA, Inc allows colleges, universities, medical and financial professionals and related clinics, hospitals and non-profit healthcare organizations to distribute our proprietary essays, photos, videos, audios and other documents; etc. However, please review copyright and usage information for each individual asset before submission to us, and/or placement on your publication or web site. Attestation references, citations and/or back-links are required. All other assets are property of the individual copyright holder.
  • OIG Fraud Warnings

    Beware of health insurance marketplace scams OIG's Most Wanted Fugitives at oig.hhs.gov

Happy Birthday Florence Nightingale [203rd]

Posted on May 12, 2023 by Dr. Marcinko

By Staff Reporters

***

***

Happy 203rd birthday to Florence Nightingale, the founder of modern nursing. She rose to fame during the Crimean War, when her hygiene standards substantially reduced the mortality rate at army hospitals. The healthcare industry still relies on some of her ideas, such as using data as a tool to improve hospital care. The “lady with the lamp” is still lighting the path forward.

***

Other Health Care Stories

  • Best Buy’s new healthcare unit is all about bringing the hospital home
  • Pharma companies lean on AI for better innovation, efficiency
  • AstraZeneca has big R&D goals to mitigate future declines in Covid-related sales
  • CITE: https://www.r2library.com/Resource

COMMENTS APPRECIATED

Thank You

***

***

Share this:

  • Share on Tumblr
  • WhatsApp
  • More
  • Email
  • Print

Like this:

Like Loading...

Filed under: "Doctors Only", Accounting, Breaking News, Drugs and Pharma, Ethics, Health Economics, Health Insurance, Health Law & Policy, Healthcare Finance, Risk Management | Tagged: AI, covid, Crimean war, Florence Nightingale, pharma | Leave a comment »

DAILY UPDATE: Inflation, Public Health and the Markets

Posted on May 11, 2023 by Dr. Marcinko

By Staff Reporters

***

***

Because the inflation data came in roughly as expected, Wall Street sees the door still open for the Federal Reserve to leave interest rates alone at its next meeting in June. That would be the first time it hasn’t raised rates at a meeting in more than a year, and a pause would offer some breathing room for the economy and financial markets.

CITE: https://www.r2library.com/Resource

***

Today is the last day of the US Covid-19 public health emergency, which has been in place since Jan. 31st, 2020. With it comes the end of certain Covid-era rules, though some telehealth protections have been extended through the end of 2024. Here’s to all the medical professionals who got us through, and a remembrance for the millions who lost their lives to Covid.

***

Brightline, a California-based mental health startup, laid off 20% of its staff this week following a data breach.
North Carolina is the latest state to consider changes to the prior authorization process that advocates say delays care.
A board member at Geisinger claims that consolidation prompted the healthcare provider to sell to Kaiser Permanente.
Texas Gov. Greg Abbott
said the state should address mental health issues in the wake of a shopping mall mass shooting, but did not call for gun control reform.
Pharma companies lean on AI for better innovation, efficiency
AstraZeneca has big R&D goals to mitigate future declines in Covid-related sales
Say goodbye to trypanophobia—this biotech is trying to turn injectable drugs into pills

***

Finally, here is where the major benchmarks ended yesterday:

  • The S&P 500 Index was up 18.47 points (0.5%) at 4137.64; the Dow Jones industrial average was down 30.48 (0.1%) at 33,531.33; the NASDAQ Composite was up 126.89 (1.0%) at 12,306.44.
  • The 10-year Treasury yield was down about 8 basis points at 3.441%.
  • CBOE’s Volatility Index was down 0.80 at 16.91.

Oilfield services providers and other energy companies were among the laggards Wednesday, pressured by a more-than 1% drop in WTI crude oil futures.

Financial sector stocks struggling to escape the effects of the bank volatility earlier this spring helped push the KWB Regional Bank Index back near a 2½-year low reached last week.

***

ORDER: https://www.routledge.com/Risk-Management-Liability-Insurance-and-Asset-Protection-Strategies-for/Marcinko-Hetico/p/book/9781498725989

ORDER: https://www.routledge.com/Comprehensive-Financial-Planning-Strategies-for-Doctors-and-Advisors-Best/Marcinko-Hetico/p/book/9781482240283

***

COMMENTS APPRECIATED

Thank You

***

Share this:

  • Share on Tumblr
  • WhatsApp
  • More
  • Email
  • Print

Like this:

Like Loading...

Filed under: "Ask-an-Advisor", Alerts Sign-Up, Alternative Investments, Drugs and Pharma, Health Economics, iMBA, Inc., Information Technology, Investing, LifeStyle | Tagged: AI, Brightline, covid, DJIA, DOW, Federal Reserve, FOMA, gold, HIT, inflation, KWB, mental health, NASDAQ, oil, pharma, S&P 500, Tele-Health, Treasury yields, volatility, WTI | Leave a comment »

DAILY UPDATE: Big Pharma Earnings, Covid, RSV Vaccine, FOMC and the Markets

Posted on May 4, 2023 by Dr. Marcinko

By Staff Reporters

MAY THE FOURTH BE WITH YOU

***

***

Many pharma companies reported earnings in the last week, and the common thread is crashing Covid-related sales.

For example, AstraZeneca’s Covid medication sales dropped $1.5b in Q1, Merck’s Covid antiviral sales fell 88% from the same quarter in 2022, and Roche’s diagnostics division sales fell 28% from Q1 2022, thanks to low Covid-test demand. Clearly, pharma companies have to figure out how to pivot their strategies in a post-Covid world.

CITE: https://www.r2library.com/Resource

***

The CDC will not continue to track Covid-19 community spread as the country enters the endemic stage of the pandemic.

***

The Food and Drug Administration approved Wednesday the first-ever vaccine to combat severe respiratory syncytial virus, or RSV. Arexvy, the new vaccine developed by GlaxoSmithKline, was approved for adults 60 and older and was 82% effective at preventing lower respiratory tract illness caused by RSV, according to trial data. It was also 94% effective in those who had at least one underlying medical condition.

***

The Federal Reserve voted unanimously to raise interest rates by a quarter point yesterday, the tenth rate hike since the central bank started its battle against inflation last March. The move comes amid ongoing fragility in the banking sector triggered partly by higher interest rates, and following the collapse of three regional banks. Markets had anticipated the rate hike, and remained fairly muted after the Fed’s announcement.

***

Finally, here’s where the major indexes ended up:

  • The S&P 500® Index was down 28.83 points at 4090.75; the Dow Jones industrial average was down 270.29 (0.8%) at 33,414.24; the NASDAQ Composite was down 55.18 (0.5%) at 12,025.33.
  • The 10-year Treasury yield was down about 7 basis points at 3.367%.
  • CBOE’s Volatility Index was up 0.52 at 18.30.

Energy companies were among the market’s weakest performers as crude oil continued a recent decline, with WTI crude futures falling more than 4% under $70 a barrel—a nearly six-week low.

Semiconductor and financial shares were also weak. The U.S. dollar index dropped sharply in the wake of the Fed announcement before rebounding.

***

ORDER: https://www.routledge.com/Risk-Management-Liability-Insurance-and-Asset-Protection-Strategies-for/Marcinko-Hetico/p/book/9781498725989

***

ORDER: https://www.routledge.com/Comprehensive-Financial-Planning-Strategies-for-Doctors-and-Advisors-Best/Marcinko-Hetico/p/book/9781482240283

***

COMMENTS APPRECIATED

Thank You

***

Share this:

  • Share on Tumblr
  • WhatsApp
  • More
  • Email
  • Print

Like this:

Like Loading...

Filed under: "Ask-an-Advisor", Alerts Sign-Up, Drugs and Pharma, Health Economics, Health Insurance, Investing | Tagged: Arexvy, Big Pharma, covid, DJIA, DOW, FDA, Federal Reserve, FOMC, Food Drug Administration, GlaxoSmithKline, gold, inflation, interest rates, Merck, NASDAQ, oil, pharma, Respiratory syncytial virus, Roche, RSV, Russell 2000, S&P 500, Treasury yields | Leave a comment »

DRUGS: Use and Abuse Epidemiology Information

Posted on February 24, 2023 by Dr. Marcinko

By Staff Reporters

***

***

“The staggering increase in methamphetamine-related deaths in the United States is largely now driven by the co-involvement of street opioids.”—Rachel Hoopsick, an assistant professor of epidemiology at the University of Illinois at Urbana-Champaign and lead researcher on a 20-year study (US News and World Report)

***

How 3 companies came to dominate the PBM market

MORE: https://medicalexecutivepost.com/2022/09/21/podcast-pbm-money-flow-explained/

***

More docs than ever use health IT for opioid prescribing

RELATED: https://medicalexecutivepost.com/2022/05/09/prescription-drug-rx-abuse/

LINK: https://www.amazon.com/Dictionary-Health-Information-Technology-Security/dp/0826149952/ref=sr_1_5?ie=UTF8&s=books&qid=1254413315&sr=1-5

***

Drug Econometrics

LINK: https://medicalexecutivepost.com/2016/11/06/are-soaring-health-care-costs-hurting-the-u-s-economy/

COMMENTS APPRECIATED

CITE: https://www.r2library.com/Resource/Title/082610254

Thank You

***

Share this:

  • Share on Tumblr
  • WhatsApp
  • More
  • Email
  • Print

Like this:

Like Loading...

Filed under: Breaking News, Career Development, Drugs and Pharma, Experts Invited, Information Technology, Research & Development, Risk Management | Tagged: Drugs, OPIOID CRISIS?, opioids, PBM, pharma, Rachel Hoopsick | Leave a comment »

PODCAST: Doctor’s Don’t Disclose Conflicts of Interest

Posted on December 13, 2022 by Dr. Marcinko

C.O.I.

By Eric Bricker MD

***

***

MORE: https://medicalexecutivepost.com/2022/10/05/video-on-doctors-money-and-conflicts-of-interest/

***

COMMENTS APPRECIATED

Thank You

CITE: https://www.r2library.com/Resource/Title/082610254

***

Product Details

ORDER: https://www.amazon.com/Business-Medical-Practice-Transformational-Doctors/dp/0826105750/ref=sr_1_9?ie=UTF8&qid=1448163039&sr=8-9&keywords=david+marcinko

***

Share this:

  • Share on Tumblr
  • WhatsApp
  • More
  • Email
  • Print

Like this:

Like Loading...

Filed under: "Doctors Only", Drugs and Pharma, Ethics, Health Economics, Health Insurance, Professional Liability | Tagged: COI, Conflicts of Interest, Don't Disclose Conflicts of Interest, Drugs, Eric Bricker MD, pharma, pharmaceuticals | Leave a comment »

AbbVie: The Economic Recession Index?

Posted on November 23, 2022 by Dr. Marcinko

The BOTOX Predictor Index?

By Staff Reporters

***

***

It’s looking more than likely that we’ll see a recession in the next year, and Americans are preparing themselves by taking steps like delaying major purchases, allocating more of their income to savings, and staying in jobs they don’t love. Another thing they’re not doing? Getting Botox. And that’s bad news for AbbVie; according to Neal Freyman of Morning Brew.

AbbVie, one of the biggest drug manufacturers in the US, brought Botox into its medical aesthetics portfolio—which also includes the popular dermal filler Juvederm—in 2020, when it bought rival drugmaker Allergan for $63 billion. AbbVie CEO Richard Gonzalez said during the company’s Oct. 28 earnings call that the company expects the aesthetics business to take a hard hit in 2023 as recession fears cause consumers to be more cautious with their spending.

“Based on all the data we’ve been observing, especially in the US, with both the consumer-confidence index and real personal consumption expenditures trending down and continued high inflation, these factors are putting pressure on consumer’s discretionary spending,” Gonzalez said.

AbbVie lowered its 2022 full-year forecast for its aesthetics business by $600 million, down to $5.3 billion. After the earnings call, AbbVie’s stock fell 4.3%. Through the third quarter of 2022, Botox has brought in $1.97 billion for the aesthetics business. The third quarter saw $637 million in cosmetic Botox sales, down from an expected $640 million. Gonzalez said he doesn’t think the hit on sales will last long, though.

***

***

“As consumer confidence improves, we would once again expect the market growth to accelerate. Our aesthetics portfolio experienced a rapid and sustained recovery following the 2008, 2009 recession,” Gonzalez said.

But Botox also faces a new competitor, called Daxxify, which just got FDA approval in September. Made by Revance Therapeutics, the drug may last longer: In clinical trials, Daxxify injections lasted six to nine months, while Botox injections typically last three months.

***

ORDER: https://www.routledge.com/Comprehensive-Financial-Planning-Strategies-for-Doctors-and-Advisors-Best/Marcinko-Hetico/p/book/9781482240283

***

COMMENTS APPRECIATED

Thank You

***

Share this:

  • Share on Tumblr
  • WhatsApp
  • More
  • Email
  • Print

Like this:

Like Loading...

Filed under: "Doctors Only", Alternative Investments, Career Development, Drugs and Pharma, Health Economics, Health Insurance, Healthcare Finance, Investing | Tagged: AbbVie, AbbVie: The Economic Recession?, botex predictor index, economic recession, Morning Brew, pharma | 1 Comment »

PHARMA: Will Americans Finally See Drug Prices Decrease?

Posted on November 4, 2022 by Dr. Marcinko

By Health Capital Consultants, LLC

***

***

According to the White House, “Americans pay two to three times as much as people in other countries for prescription drugs, and one in four Americans who take prescription drugs struggle to afford their medications. Nearly 3 in 10 American adults who take prescription drugs say that they have skipped doses, cut pills in half, or not filled prescriptions due to cost.” In an effort to combat this growing crisis, both the federal government and private companies have taken a number of steps over the past year aiming to lower drug prices. This Health Capital Topics article will review those actions and the potential unintended consequences of these actions.
(Read more…)

COMMENTS APPRECIATED

Thank You

CITE: https://www.r2library.com/Resource/Title/082610254

ORDER: https://www.amazon.com/Hospitals-Healthcare-Organizations-Management-Operational/dp/1439879907/ref=sr_1_4?s=books&ie=UTF8&qid=1334193619&sr=1-4

***

Share this:

  • Share on Tumblr
  • WhatsApp
  • More
  • Email
  • Print

Like this:

Like Loading...

Filed under: "Doctors Only", Drugs and Pharma, Experts Invited, Glossary Terms, Health Economics, Health Insurance | Tagged: drug prices, Drugs, Health Capital Consultants LLC, PBM, pharma, pharmacy, Pharmacy Benefits Managers, Will Americans Finally See Drug Prices Decrease? | Leave a comment »

CVS, Walgreens and Walmart: Opioid Settlement

Posted on November 3, 2022 by Dr. Marcinko

By Staff Reporters

***

***

CVS, Walgreens, and Walmart agree to pay $13 billion over opioids

The pharmacy chains have reached a tentative deal to settle thousands of lawsuits brought by state and local governments that accuse them of contributing to the opioid epidemic.

If the deal goes through, CVS and Walgreens will each cough up around $5 billion, and Walmart will reportedly be on the hook for $3 billion.

***

COMMENTS APPRECIATED

Thank You

***

ORDER: https://www.routledge.com/Risk-Management-Liability-Insurance-and-Asset-Protection-Strategies-for/Marcinko-Hetico/p/book/9781498725989

***

Share this:

  • Share on Tumblr
  • WhatsApp
  • More
  • Email
  • Print

Like this:

Like Loading...

Filed under: Breaking News, Drugs and Pharma, Ethics, Health Insurance, Risk Management | Tagged: CVs, Drugs, opioids, pharma, pharmaceuticals, Walgreen's, Walmart | Leave a comment »

Supreme Court Hears Oral Arguments on 340B Drug Pricing Cuts

Posted on January 19, 2022 by Dr. Marcinko

BY HEALTH CAPITAL CONSULTANTS, LLC

***

Supreme Court Hears Oral Arguments on 340B Cuts

On November 30, 2021, the U.S. Supreme Court heard oral arguments regarding the challenges arising from the cuts made by the Centers of Medicare & Medicaid Services (CMS) to the 340B Drug Pricing Program.

The 340B Drug Pricing Program allows hospitals and clinics that treat low-income, medically underserved patients to purchase certain “specified covered outpatient drugs” at discounted prices (applying a ceiling to what drug manufacturers may charge certain healthcare facilities) – 25% to 50% of what providers would typically pay – and then receive reimbursement pursuant to the rates set forth in the Outpatient Prospective Payment System (OPPS) at the same rate as all other providers. (Read more…)

***

HEALTH ECONOMICS CITE: https://www.r2library.com/Resource/Title/0826102549

PODCAST: https://medicalexecutivepost.com/2021/08/27/podcast-hospital-340-b-drug-programs/

***

***

***

***

Share this:

  • Share on Tumblr
  • WhatsApp
  • More
  • Email
  • Print

Like this:

Like Loading...

Filed under: Accounting, Breaking News, Drugs and Pharma, Experts Invited, Videos | Tagged: 340-B Drug Program, Centers of Medicare & Medicaid Services, CMS, CMS drug pricing program, Drugs, Health Capital Consultants LLC, Health Economics, OPPS, Outpatient Prospective Payment System, pharma, pharmacy | 1 Comment »

PODCAST: Prescription Patient Assistance Programs

Posted on January 11, 2022 by Dr. Marcinko

BY ERIC BRICKER MD

With 43 Million Americans Having Lost Their Job at Some Point During the Pandemic and About 1/2 Those Jobs Providing Health Insurance… the 1st Group–People Who Do Not Have Health Insurance–Needs to Be Aware of How These Programs Work.

In this Video You Will Learn the Patient Assistance Program Process for:

1) 2 of the Most Common Types of Insulin

2) The Highest-Revenue Medication in America: Humira

**Note: At the Time of the Video’s Recording, the Unemployment Rate in the US was 15%. As of November 2021, the Unemployment Rate is 4.2%.

***

***

COMMENTS APPRECIATED

Subscribe to the Medical Executive-Post

***

***

CITE: https://www.r2library.com/Resource/Title/082610254

***

Share this:

  • Share on Tumblr
  • WhatsApp
  • More
  • Email
  • Print

Like this:

Like Loading...

Filed under: Drugs and Pharma, Ethics, Experts Invited, Glossary Terms, Health Economics, Health Insurance, Healthcare Finance, iMBA, Inc., Videos | Tagged: Eric Bricker MD, Health Insurance, humira, insulin, Patient Assistance Programs, PBMs, pharma, pharmaceuticals, Prescription Patient Assistance Programs | 1 Comment »

PODCAST: The 10 Top Technology Trends Shaping the Future of the Pharma

Posted on October 8, 2021 by Dr. Marcinko

THE CULTURAL SHIFT

Dr. Bertalan Meskó, MD

The pharma industry has taken a big swung into digital transformation. All participants invest in digital health topics.

But as with all trending issues, and there is a lot of fuss that is hard to see through. As the medical community increasingly acknowledges the importance of digital health, the cultural shift we so often talk about is still a way to go. To change that, the first step is always getting to know what’s coming.

In this article, with podcast, Bert collected the trends changing the pharmaceutical industry.

ESSAY AND PODCAST: https://medicalfuturist.com/top-10-trends-shaping-future-pharma/?utm_source=The%20Medical%20Futurist%20Newsletter&utm_campaign=3a501b1978-EMAIL_CAMPAIGN_2021_09_05_Resend&utm_medium=email&utm_term=0_efd6a3cd08-3a501b1978-399696053&mc_cid=3a501b1978&mc_eid=40fee31c25#

YOUR THOUGHTS AND COMMENTS ARE APPRECIATED.

Thank You

***

****

Click to access foreword-mata.pdf

Share this:

  • Share on Tumblr
  • WhatsApp
  • More
  • Email
  • Print

Like this:

Like Loading...

Filed under: "Doctors Only", Drugs and Pharma, Experts Invited, Information Technology | Tagged: Dr. Bertalan Meskó, Drugs, medical digital transformation, pharma, pharma future, pharma trends | Leave a comment »

PODCASTS: FDA Pharmaceutical Industry Ties

Posted on September 15, 2021 by Dr. Marcinko

CONFLICTS OF INTEREST?

The New York Times Had an Excellent Article on the FDA on September 2, 2021.

The Article Described How the FDA Began Receiving Funding from the Pharmaceutical Industry Itself to Pay for FDA Employee Salaries in 1992–a Potential Conflict-of-Interest. Subsequently, a Study Found that 1/3 of Drugs Approved by the FDA Were Found to Have Safety Problems from 2000 -2010. Another Potential Conflict-of-Interest is Number of FDA Regulators Who Leave Their Positions to Take High-Paying Jobs at Pharmaceutical Companies.

By Eric Bricker MD

FDA rescinds emergency authorization for COVID-19 antibody treatment  bamlanivimab | TheHill

PODCAST:

***

YOUR COMMENTS ARE APPRECIATED.

Thank You

****

***

Share this:

  • Share on Tumblr
  • WhatsApp
  • More
  • Email
  • Print

Like this:

Like Loading...

Filed under: "Doctors Only", Drugs and Pharma, Ethics, Experts Invited, Op-Editorials, Videos | Tagged: Big Pharma, DEA, Drugs, Eric Bricker MD, FDA, NYT, pharma, pharma conflicts, pharmaceutical industry | Leave a comment »

The PBMI Innovation Challenge

Posted on August 6, 2021 by Dr. Marcinko

There’s still time!
Submit your innovative solution in patient health management to the Pharmacy Benefit Management Institute (PBMI) Innovation Challenge by August 6, 2021 for the chance to be among one of the 5 finalists selected to pitch their ideas before a panel of judges at the PBMI 2021 Annual Meeting!




Be sure to submit your idea by August 6, 2021 for the chance to be featured in an upcoming issue of Managed Healthcare Executive with a full-year integrated marketing program valued at over $100K, in addition to formal acknowledgment at this year’s PBMI Conference.

REGISTER: https://events.pbmi.com/event/31593a7e-d661-4ea5-abf2-5aa6473e1a14/summary

***

Share this:

  • Share on Tumblr
  • WhatsApp
  • More
  • Email
  • Print

Like this:

Like Loading...

Filed under: Drugs and Pharma | Tagged: Drugs, PBM, pharma, Pharmacy Benefit Mangers | 1 Comment »

Peri-Operative MEs and ADEs

Posted on December 14, 2015 by Dr. Marcinko

Join Our Mailing List

One in Twenty [1/20]

By http://www.MCOL.com

***

ImageProxy

***

Conclusion

Your thoughts and comments on this ME-P are appreciated. Feel free to review our top-left column, and top-right sidebar materials, links, URLs and related websites, too. Then, subscribe to the ME-P. It is fast, free and secure.

Speaker: If you need a moderator or speaker for an upcoming event, Dr. David E. Marcinko; MBA – Publisher-in-Chief of the Medical Executive-Post – is available for seminar or speaking engagements. Contact: MarcinkoAdvisors@msn.com

OUR OTHER PRINT BOOKS AND RELATED INFORMATION SOURCES:

  • PRACTICES: www.BusinessofMedicalPractice.com
  • HOSPITALS: http://www.crcpress.com/product/isbn/9781466558731
  • CLINICS: http://www.crcpress.com/product/isbn/9781439879900
  • ADVISORS: www.CertifiedMedicalPlanner.org
  • FINANCE: Financial Planning for Physicians and Advisors
  • INSURANCE: Risk Management and Insurance Strategies for Physicians and Advisors
  • Dictionary of Health Economics and Finance
  • Dictionary of Health Information Technology and Security
  • Dictionary of Health Insurance and Managed Care

[HEALTH INSURANCE, MANAGED CARE, ECONOMICS, FINANCE AND HEALTH INFORMATION TECHNOLOGY COMPANION DICTIONARY SET]

Product DetailsProduct DetailsProduct Details

[Mike Stahl PhD MBA] *** [Foreword Dr.Mata MD CIS] *** [Dr. Getzen PhD]

***

Share this:

  • Share on Tumblr
  • WhatsApp
  • More
  • Email
  • Print

Like this:

Like Loading...

Filed under: Drugs and Pharma, Quality Initiatives | Tagged: ADEs, Drugs, MEs, pharma, www.MCOL.com | 1 Comment »

National Health Expenditure Growth

Posted on January 16, 2014 by Dr. Marcinko

Join Our Mailing List

A Report from the Office of the Actuary

Source: Centers for Medicare & Medicaid Services

According to the Centers for Medicare & Medicaid Services (CMS) Office of the Actuary, overall national health expenditures grew at an annual rate of 3.7 percent in 2012, marking the fourth consecutive year of low growth. Health spending as a share of gross domestic product fell slightly from 17.3 percent in 2011 to 17.2 percent in 2012.

Private Insurance

Private health insurance spending growth remained low. Private health insurance spending continued to grow at a low rate, increasing 3.2 percent in 2012 compared to 3.4 percent growth in 2011. Medicare spending growth continued to be low. Despite a large uptick in Medicare enrollment, Medicare spending growth slowed slightly in 2012, increasing by 4.8 percent compared to 5.0 percent growth in 2011.

The Totals for MC/MD

Total Medicare spending per enrollee grew by only 0.7 percent in 2012. Medicaid spending continued to grow at a historically low rate. Total Medicaid spending grew 3.3 percent in 2012. While an increase over 2011, this increase still represents historically low overall growth rates tied to improved economic conditions, as well as efforts by states to control costs.

Rx Drugs

Prescription drug spending growth was low. Retail prescription drug spending slowed in 2012, growing only 0.4 percent as the result of numerous drugs losing their patent protection, leading to increased sales of lower-cost generics. Nursing home spending growth slowed.

Pharma

Assessment

Spending for freestanding nursing care facilities and continuing care retirement communities increased by only 1.6 percent in 2012, down from 4.3 percent growth in 2011, due to a one-time Medicare rate adjustment for skilled nursing facilities.

Conclusion

Your thoughts and comments on this ME-P are appreciated. Feel free to review our top-left column, and top-right sidebar materials, links, URLs and related websites, too. Then, subscribe to the ME-P. It is fast, free and secure.

Link: http://feeds.feedburner.com/HealthcareFinancialsthePostForcxos

Speaker: If you need a moderator or speaker for an upcoming event, Dr. David E. Marcinko; MBA – Publisher-in-Chief of the Medical Executive-Post – is available for seminar or speaking engagements. Contact: MarcinkoAdvisors@msn.com

OUR OTHER PRINT BOOKS AND RELATED INFORMATION SOURCES:

DICTIONARIES: http://www.springerpub.com/Search/marcinko
PHYSICIANS: www.MedicalBusinessAdvisors.com
PRACTICES: www.BusinessofMedicalPractice.com
HOSPITALS: http://www.crcpress.com/product/isbn/9781466558731
CLINICS: http://www.crcpress.com/product/isbn/9781439879900
BLOG: www.MedicalExecutivePost.com
FINANCE: Financial Planning for Physicians and Advisors
INSURANCE: Risk Management and Insurance Strategies for Physicians and Advisors

Product DetailsProduct Details

Product Details

Share this:

  • Share on Tumblr
  • WhatsApp
  • More
  • Email
  • Print

Like this:

Like Loading...

Filed under: Drugs and Pharma, Health Economics, Health Insurance | Tagged: Centers for Medicare & Medicaid Services, CMS, Drugs, National Health Expenditure Growth, pharma, Retail prescription drug spending | 1 Comment »

Doctors on Drugs

Posted on June 23, 2012 by Dr. Marcinko

Join Our Mailing List

Profitable Prescriptions?

Increasing in costs each year, prescription pills are one of the most profitable and dominating industries in the nation, with annual sales in the hundreds of billions. Prescribed medications constitute a significant bulk of work that medical coders must transcribe.

The Rx Pill Industry

Shockingly, the prescription pill industry uses questionable practices to increase their bottom line, and in turn, increase coding workload through unnecessary prescriptions. Though pharmaceutical companies have long-earned a reputation for wooing doctors with gifts, bribes, and incentives, it was only revealed in recent years that they’ve also been paying doctors huge sums of money to promote certain products. And, some and doctors are taking up on these offers.

These pre-selected medications are not only violating a conflict of interest, but they can also be largely responsible for increases in patient and insurance costs: a doctor may feel obligated to prescribe an expensive “sponsored” medication over a cheaper alternative.

Assessment

This in turn, is reflected on the overall rising cost of healthcare, which unfortunately, is exactly what the doctor ordered.

Conclusion

Your thoughts and comments on this ME-P are appreciated. Feel free to review our top-left column, and top-right sidebar materials, links, URLs and related websites, too. Then, subscribe to the ME-P. It is fast, free and secure.

Link: http://feeds.feedburner.com/HealthcareFinancialsthePostForcxos

Speaker: If you need a moderator or speaker for an upcoming event, Dr. David E. Marcinko; MBA – Publisher-in-Chief of the Medical Executive-Post – is available for seminar or speaking engagements. Contact: MarcinkoAdvisors@msn.com

Our Other Print Books and Related Information Sources:

Health Dictionary Series: http://www.springerpub.com/Search/marcinko

Practice Management: http://www.springerpub.com/product/9780826105752

Physician Financial Planning: http://www.jbpub.com/catalog/0763745790

Medical Risk Management: http://www.jbpub.com/catalog/9780763733421

Hospitals: http://www.crcpress.com/product/isbn/9781439879900

Physician Advisors: www.CertifiedMedicalPlanner.org

Product DetailsProduct DetailsProduct Details

Share this:

  • Share on Tumblr
  • WhatsApp
  • More
  • Email
  • Print

Like this:

Like Loading...

Filed under: Drugs and Pharma, Ethics, Glossary Terms | Tagged: “sponsored” medication, Doctors on Drugs, pharma, pharmaceutical companies, prescription pills, Rx drugs | 7 Comments »

Doctors on Drugs?

Posted on December 7, 2011 by Dr. Marcinko

Sponsored Medications Increase MDs Bottom Line

Join Our Mailing List

Increasing in costs each year, prescription pills are one of the most profitable and dominating industries in the nation, with annual sales in the hundreds of billions. Prescribed medications constitute a significant bulk of work that medical coders must transcribe.

Shockingly, the prescription pill industry has questionable practices to increase their bottom line, and in turn, increase coding workload through unnecessary prescriptions.

Though pharmaceutical companies have long-earned a reputation for wooing doctors with gifts, bribes, and incentives, it was only revealed in recent years that they’ve also been paying doctors huge sums of money to promote certain products – and doctors are taking up these offers. These pre-selected medications are not only violating a conflict of interest, they can be largely responsible for increases in patient and insurance costs: a doctor may feel obligated to prescribe an expensive “sponsored” medication over a cheaper alternative.

This in turn, is reflected on the overall rising cost of healthcare, which unfortunately, is exactly what the doctor ordered.

Source: Medical Billing and Coding

Conclusion                

And so, your thoughts and comments on this ME-P are appreciated. Feel free to review our top-left column, and top-right sidebar materials, links, URLs and related websites, too. Then, subscribe to the ME-P. It is fast, free and secure.

Link: http://feeds.feedburner.com/HealthcareFinancialsthePostForcxos

Speaker: If you need a moderator or speaker for an upcoming event, Dr. David E. Marcinko; MBA – Publisher-in-Chief of the Medical Executive-Post – is available for seminar or speaking engagements. Contact: MarcinkoAdvisors@msn.com

Our Other Print Books and Related Information Sources:

Health Dictionary Series: http://www.springerpub.com/Search/marcinko

Practice Management: http://www.springerpub.com/product/9780826105752

Physician Financial Planning: http://www.jbpub.com/catalog/0763745790

Medical Risk Management: http://www.jbpub.com/catalog/9780763733421

Healthcare Organizations: www.HealthcareFinancials.com

Physician Advisors: www.CertifiedMedicalPlanner.com

Subscribe Now: Did you like this Medical Executive-Post, or find it helpful, interesting and informative? Want to get the latest ME-Ps delivered to your email box each morning? Just subscribe using the link below. You can unsubscribe at any time. Security is assured.

Link: http://feeds.feedburner.com/HealthcareFinancialsthePostForcxos

Sponsors Welcomed: And, credible sponsors and like-minded advertisers are always welcomed.

Link: https://healthcarefinancials.wordpress.com/2007/11/11/advertise

Product Details

Share this:

  • Share on Tumblr
  • WhatsApp
  • More
  • Email
  • Print

Like this:

Like Loading...

Filed under: Drugs and Pharma, Ethics | Tagged: Drugs, pharma, pharmaceutical companies, prescription pills, sponsored drugs | 1 Comment »

Enter Margaret Hamburg

Posted on April 10, 2009 by Dr. Marcinko

The New FDA Nominee

By Staff Reporters

lombard-courtAccording to Tracy Staton and FiercePharma on April 7, Dr. Marcia Angell, former New England Journal of Medicine editor-in-chief and current Harvard Medical School lecturer, wrote a column in the Washington Post that set out a list of seven goals for Margaret Hamburg who awaits senate confirmation as FDA chief.

A New Book

Now, Angell has a particular point of view; she’s published a book called The Truth About the Drug Companies [How they Deceive us and What to Do About It]. Here they are, presented for your critique and consideration by the new FDA chief:

  • Repeal the Prescription Drug User Fee Act because it puts “the FDA on the payroll of the industry it regulates.”
  • Consultants for drug companies should be banned from advisory committees.
  • Enforce FDA mandates on post-marketing studies.
  • Review generics as quickly as it checks out branded meds.
  • Require drug-makers to compare their new drugs with similar existing meds.
  • Cease surrogate drug endpoints.
  • Bar DTC ads for three years after a new drug is approved.

Assessment

What has she missed? Are these guidelines fair or not? Will they be advocated by Hamburg, if confirmed?  

Conclusion

And so, your thoughts and comments on this Medical Executive-Post are appreciated? Feel free to review our top-left column, and top-right sidebar materials, links, URLs and related websites, too. Then, be sure to subscribe to the ME-P. It is fast, free and secure.

Link: http://feeds.feedburner.com/HealthcareFinancialsthePostForcxos

Speaker: If you need a moderator or speaker for an upcoming event, Dr. David E. Marcinko; MBA – Publisher-in-Chief of the Executive-Post – is available for seminar or speaking engagements. Contact: MarcinkoAdvisors@msn.com  or Bio: www.stpub.com/pubs/authors/MARCINKO.htm

Get our Widget: Get this widget!

Our Other Print Books and Related Information Sources:

Practice Management: http://www.springerpub.com/prod.aspx?prod_id=23759

Physician Financial Planning: http://www.jbpub.com/catalog/0763745790

Medical Risk Management: http://www.jbpub.com/catalog/9780763733421

Healthcare Organizations: www.HealthcareFinancials.com

Health Administration Terms: www.HealthDictionarySeries.com

Physician Advisors: www.CertifiedMedicalPlanner.com

Subscribe Now: Did you like this Medical Executive-Post, or find it helpful, interesting and informative? Want to get the latest ME-Ps delivered to your email box each morning? Just subscribe using the link below. You can unsubscribe at any time. Security is assured.

Link: http://feeds.feedburner.com/HealthcareFinancialsthePostForcxos

Share this:

  • Share on Tumblr
  • WhatsApp
  • More
  • Email
  • Print

Like this:

Like Loading...

Filed under: Alerts Sign-Up, Book Reviews, Breaking News, Drugs and Pharma, Ethics, Health Law & Policy | Tagged: big-pharma, drug, drug companies, DTC, FDA, generic drugs, Marcia Angell, Margaret Hamburg, NEJM, pharma, pharmaceuticals, trade drugs, Washington Post | 1 Comment »

  • Calendar

    • June 2023
      M T W T F S S
       1234
      567891011
      12131415161718
      19202122232425
      2627282930  
      « May    
  • Advertising Info:

    • Advertise with Us!
    • Classified Ads
    • Dr. David E. Marcinko MBA
    • ME-P MAST HEAD
    • Support Med Executive-Post
  • Book Offerings:

    • Business of Medical Practice [Transformational Health 2.0 Skills for Doctors]
    • Comprehensive Financial Planning Strategies for Doctors and Advisors [Best Practices from Leading Certified Medical Planners™]
    • Financial Management Strategies for Hospitals [Tools, Techniques, Checklists and Case Studies]
    • Financial Planning Handbook For Physicians and Advisors
    • Hospitals & Healthcare Organizations [Management Strategies, Operational Techniques, Tools, Templates, and Case Studies]
    • Insurance and Risk Management Strategies for Physicians and Advisors
    • Risk Management, Liability Insurance, and Asset Protection Strategies for Doctor and Advisors [Best Practices from Leading Consultants and Certified Medical Planners™]
  • Dictionary Offerings:

    • Dictionary of Health Economics and Finance
    • Dictionary of Health Information Technology and Security
    • Dictionary of Health Insurance and Managed Care
  • Dr. David Marcinko [Publication List]

    • Google Scholar Search
    • National Institute of Health – Part I
    • National Institute of Health – Part II
  • Education Online:

    • CERTIFIED MEDICAL PLANNER® Program for Financial Advisors and Consultants
  • Health Dictionary Series Wiki Project

    • e-Health Dictionary Series®
  • Lower Extremity Medicine & Surgery

    • e-Podiatry Consent Forms®
    • Podiatry Board Exams and State Licensure Preparation
  • Pending NIHCM Grant Applications:

    • "Exposing Hobson's Choice and Rationing in Medicine"
  • Practice Lists:

    • eMRs, HIT and Security [Checklists & Case Models]
    • Medical Office Checklists [Checklists & Case Models]
    • Practice Case Examples [Checklists & Case Models]
  • Professor Marcinko

    • Comprehensive [CV] Website
    • Curriculum Development
    • Virtual Internet Chatting
  • Related Blogs:

    • Alert and Oriented
    • Association of Private Enterprise Education
    • Ayn Rand Institute
    • Benjamin Rush Institute
    • Data Breaches
    • e-Financial Consultants
    • European Center of Austrian Economics Foundation
    • FLIP IT Consulting
    • Foundation for Economic Education
    • Free Market Medical Association
    • Health Capital Consultants
    • Health Care Renewal
    • Health Economics
    • Healthcare Town Hall
    • International Health Economics Association
    • Library of Economics and Liberty
    • Ludwig von Mises Institute
    • Society for the Development of Austrian Economics
    • Taking Hayek Seriously
    • The Austrian Economics Center
    • Top 100 Economics Blogs
    • Uneasy Money
    • www.fi360.com
  • Speaker's Bureau:

    • Dr. David E. Marcinko MBA CMP™ [Publisher-in-Chief]
  • Thought-Leaders:

    • Ahmad Hashem; MD, PhD
    • Andrew Schwartz CPA
    • Anju D. Jessani; MBA APM®
    • Anthony Silva; MD MBA
    • Brian J. Knabe; MD CFP® CMP™
    • Carol S. Miller BSN MBA CMP™ [Hon]
    • Darrell K. Pruitt; DDS
    • David B. Nash; MD, MBA
    • David K. Luke MIM CMP™
    • Edwin Morrow; CFP® RFC
    • Edwin P. Morrow III; J.D., LL.M., MBA, CFP®, RFC®
    • Eric A. Dover MD
    • Frank A. Cappiello; PhD MBA
    • Gary L. Bode DPM CPA MSA CMP™ [Hon]
    • Ike Devji; JD
    • J. Christopher Miller JD
    • J. Wesley Boyd MD PhD
    • James Winston Phillips MD JD LLM MBA
    • Kernan T. Manion MD
    • Lloyd M. Krieger; MD, MBA
    • Michael J. Stahl; PhD MBA
    • Michael Lawrence Langan MD
    • Neil H. Baum MD MBA
    • Perry D'Alessio CPA
    • Richard A. Berning; MD
    • Rick Kahler MSFS CFP®
    • Rick Mata; MD, MS, CMP™
    • Shahid N. Shah; MS
    • Somnath Basu; PhD, MBA
    • Susan L. Theuns; PA-C, CPC, CHC, MA
    • Thomas A. Muldowney MSFS CFP AIF CMP™
    • Thomas E. Getzen; PhD
    • Timothy McIntosh MBA MPH CFP® CMP™ [Hon]
    • Vitaliy N. Katsenelson CFA
  • White Papers:

    • Competitive Modeling and Analysis in Healthcare

Blog at WordPress.com. WP Designer.

  • Follow Following
    • The Leading Business Education Network for Doctors, Financial Advisors and Health Industry Consultants
    • Join 1,289 other followers
    • Already have a WordPress.com account? Log in now.
    • The Leading Business Education Network for Doctors, Financial Advisors and Health Industry Consultants
    • Customize
    • Follow Following
    • Sign up
    • Log in
    • Report this content
    • View site in Reader
    • Manage subscriptions
    • Collapse this bar
 

Loading Comments...
 

    %d bloggers like this: